Toth Financial Advisory Corp Acquires 4,505 Shares of Krystal Biotech, Inc. $KRYS

Toth Financial Advisory Corp lifted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 75,083.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,511 shares of the company’s stock after buying an additional 4,505 shares during the period. Toth Financial Advisory Corp’s holdings in Krystal Biotech were worth $1,677,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its stake in Krystal Biotech by 58.4% in the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after purchasing an additional 39,000 shares during the period. Fisher Asset Management LLC bought a new stake in Krystal Biotech during the fourth quarter worth $933,000. Principal Financial Group Inc. lifted its stake in Krystal Biotech by 15.6% in the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after purchasing an additional 22,231 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Krystal Biotech by 152.1% during the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares during the last quarter. Finally, Biondo Investment Advisors LLC increased its holdings in shares of Krystal Biotech by 31.3% during the fourth quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after purchasing an additional 16,245 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on KRYS. Bank of America raised their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. TD Cowen increased their price objective on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $365.40.

Krystal Biotech Stock Down 1.7%

KRYS stock opened at $351.46 on Friday. The firm has a market capitalization of $10.40 billion, a PE ratio of 44.04 and a beta of 0.53. Krystal Biotech, Inc. has a twelve month low of $136.73 and a twelve month high of $382.54. The stock has a 50-day simple moving average of $348.64 and a two-hundred day simple moving average of $304.16.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 51,000 shares of company stock worth $16,278,020 over the last three months. Company insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.